1. Gatti G, Barzaghi N, Acuto G et al. A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):331-5.
2. Barbagallo Sangiorgi G, Barbagallo M, Giordano M, et al. alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Ann N Y Acad Sci. 1994;717:253-69
3. Parnetti L, Abate G, Bartorelli L et al. Multicentre study of l-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type. Drugs Aging. 1993 Mar-Apr;3(2):159-64.
4. Choudhary D, Bhattacharyya S, Bose S. Efficacy and Safety of Ashwagandha (Withania somnifera (L.) Dunal) Root Extract in Improving Memory and Cognitive Functions. J Diet Suppl. 2017;14(6):599-612.
5. Ghosal S, Lal J, Srivastava R, and et al. Immunomodulatory and CNS effects of sitoindosides 9 and 10, two new glycowithanolides from Withania somnifera. Phytotherapy Research 1989;3(5):201-206.
6. Chengappa KN, Bowie CR, Schlicht PJ, Fleet D, Brar JS, Jindal R. Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder. J Clin Psychiatry. 2013;74(11):1076-83.
7. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev 2000, 5:334-46.
8. Bhattacharya, S. K., Bhattacharya, A., Sairam, K., and Ghosal, S. Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: an experimental study. Phytomedicine 2000, 7(6):463-469.
9. Archana R, Namasivayam A. Antistressor effect of Withania somnifera. J Ethnopharmacol 1999, 64:91-3.
10. Shah N, Singh R, et al. Combinations of Ashwagandha leaf extracts protect brain-derived cells against oxidative stress and induce differentiation. PLoS One. 2015;10(3):e0120554.
11. Tohda, C. [Overcoming several neurodegenerative diseases by traditional medicines: the development of therapeutic medicines and unraveling pathophysiological mechanisms]. Yakugaku Zasshi 2008;128(8):1159-1167.
12. Mori K, Obara Y, Moriya T, Inatomi S, Nakahata N. Effects of Hericium erinaceus on amyloid ß(25-35) peptide-induced learning and memory deficits in mice. Biomed Res. 2011, 32(1):67-72.
13. Cheng JH, Tsai CL, Lien YY, Lee MS, Sheu SC. High molecular weight of polysaccharides from Hericium erinaceus against amyloid beta-induced neurotoxicity. BMC Complement Altern Med. 2016, 16(1):170.
14. Lulita MF, Cuello AC. Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome. Trends Pharmacol Sci. 2014;35(7):338-48.
15. Kuo HC, Lu CC, Shen CH, et al. Hericium erinaceus mycelium and its isolated erinacine A protection from MPTP-induced neurotoxicity through the ER stress, triggering an apoptosis cascade. J Transl Med. 2016, 14:78.
16. Liu J, DU C, Wang Y, Yu Z. Anti-fatigue activities of polysaccharides extracted from Hericium erinaceus. Exp Ther Med. 2015, 9(2):483-487.
17. Nagano M, Shimizu K, Kondo R, et al. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res. 2010;31(4):231-7.
18. Mancini E, Beglinger C, Drewe J, et al. Green tea effects on cognition, mood and human brain function: A systematic review. Phytomedicine. 2017;34:26-37.
19. Sarris J, Byrne GJ, et al. L-theanine in the adjunctive treatment of generalized anxiety disorder: A double-blind, randomised, placebo-controlled trial. J Psychiatr Res. 2019;110:31-37.
20. Bukowski JF, Percival S. l-Theanine intervention enhances human gammadelta T lymphocyte function. Nutr. Rev. 2008;66:96-102.
21. Dietz C, Dekker M. Effect of Green Tea Phytochemicals on Mood and Cognition. Curr Pharm Des. 2017;23(19):2876-2905.
22. Camfield DA, Stough C, Farrimond J, Scholey AB. Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis. Nutrition Reviews. 2014;72(8):507-522.
23. Mason R. 200 mg of zen: l-Theanine boosts alpha waves, promotes alert relaxation. Altern. Complement. Ther. 2001;7:91-95.
24. Kimura K, Ozeki M, et al. l-Theanine reduces psychological and physiological stress responses. Biol. Psychol. 2007;74:39-45.
25. Demedio G, Trovarelli G, Piccinin G, and et al. The effect of cytidine-diphosphate choline (cdp-choline) on brain lipid changes during aging. Journal Of Neuroscience Research 1984;11(1):49-58.
26. Babb SM, Wald LL, Cohen BM, et al. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology.(Berl.) 2002;161(3):248-254.
27. Eberhardt, R., Birbamer, G., Gerstenbrand, F., Rainer, E., and Traegner, H. Citicoline in the treatment of Parkinson's disease. Clin.Ther 1990;12(6):489-495.
28. Barrachina, M., Secades, J., Lozano, R., Gomez-Santos, C., Ambrosio, S., and Ferrer, I. Citicoline increases glutathione redox ratio and reduces caspase-3 activation and cell death in staurosporine-treated SH-SY5Y human neuroblastoma cells. Brain.Res 12-6-2002;957(1):84-90.
29. Garciamas A, Rossinol A, and Roca M. Effects of citicholine in subcortical dementia associated with Parkinsons-disease assessed by quantified electroencephalography. Clinical Therapeutics 1992;14(5):718-729.
30. Radad K, Gille G, Xiaojing J, Durany N, and Rausch W-D. CDP-choline reduces dopaminergic cell loss induced by MPP-super(+) and glutamate in primary mesencephalic cell culture. International Journal of Neuroscience 2007;117(7):985-998.
31. Kim HY, Huang BX, Spector AA. Phosphatidylserine in the brain: metabolism and function. Prog Lipid Res. 2014;56:1-18.
32. Mozzi R, Buratta S, Goracci G. Metabolism and functions of phosphatidylserine in mammalian brain. Neurochem Res. 2003;28:195-214.
33. Thorne Research I. Phosphatidylserine. Altern Med Rev. 2008;13:245.
34. Nishizuka Y. Turnover of inositol phospholipids and signal transduction. Science. 1984;225:1365-70.
35. Chaung HC, Chang CD, Chen PH, Chang CJ, Liu SH, Chen CC. Docosahexaenoic acid and phosphatidylserine improves the antioxidant activities in vitro and in vivo and cognitive functions of the developing brain. Food Chem. 2013;138:342-7.
36. Amaducci L, Crook TH, Lippi A, et al. Use of phosphatidylserine in Alzheimer’s disease. Ann N Y Acad Sci. 1991;640:245-9.
37. Villardita C, Grioli S, Salmeri G, et al. Multicentre clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Clin Trials J. 1987;24:84-93.
38. Hirayama S, Terasawa K, Rabeler R, et al. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebocontrolled clinical trial. J Hum Nutr Diet. 2014;27(Suppl 2):284-91.
39. Manor I, Magen A, Keidar D, et al. The effect of phosphatidylserine containing Omega3 fattyacids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebocontrolled trial, followed by an open-label extension. Eur Psychiatry. 2012;27:335-42.
40. Olsson EM, von Schéele B, Panossian AG. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract shr-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med. 2009;75(2):105-12.
41. Kelly GS. Rhodiola rosea: a possible plant adaptogen. Altern Med Rev 2001;6:293-302.
42. Abidov M, Crendal F, Grachev S, Seifulla R, Ziegenfuss T.  Effect of extracts from Rhodiola rosea and Rhodiola crenulata (Crassulaceae) roots on ATP content in mitochondria of skeletal muscles. Bull Exp Biol Med. 2003;136(6):585-7.
43. De Bock K, Eijnde BO, Ramaekers M, Hespel P. Acute Rhodiola rosea intake can improve endurance exercise performance. Int J Sport Nutr Exerc Metab 2004;14:298-307.
44. Bystritsky A, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med 2008;14:175-80.
45. Darbinyan G, Aslanyan G, Amroyan E. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry 2007;61:343-8.
46. Xu SS, Cai ZY, Qu ZW, et al. Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao 1999;20:486-90.
47. Zhang, Z., Wang, X., Chen, Q., Shu, L., Wang, J., and Shan, G. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]. Zhonghua Yi Xue Za Zhi 7-25-2002;82(14):941-944.
48. Zhang, M. Evaluation of clinical effect and safety of huperzine A in treating 52 Alzheimer's disease. Journal of New Drugs and Clinical Remedies 2006;25:693.
49. Du ZM, Li SL, and Yang CF. [A randomised study of huperzine: a therapy on senile amnestic syndrome]. Chinese Journal of Geriatrics 1996;15(3):180.
50. Zheng W, Xiang YQ, Li XB, et al. Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis. Hum Psychopharmacol 2016;31(4):286-295.
51. Rafii MS, Walsh S, Little JT, et al.; Alzheimer's Disease Cooperative Study. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 2011;76(16):1389-1394.
52. Xiong ZQ, Cheng DH, Tang XC. Effects of huperzine A on nucleus basalis magnocellularis lesion-induced spatial working memory deficit. Chung Kuo Yao Li Hsueh Pao 1998;19:128-132.
53. Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li Xue Bao 1995;16:391-395.
54. Wang, W. Effect of huperzine A on memory function of patients with mild cognitive impairment. Zhongguo Linchuang Kangfu 2005;9(8):23.
55. Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li Xue Bao 1995;16:391-5.
56. Kongkeaw C, Dilokthornsakul P, et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528-35.
57. Russo A, Borrelli F. Bacopa monniera, a reputed nootropic plant: an overview. Phytomedicine. 2005;12(4):305-17.
58. Stough C, Lloyd J, Clarke J, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl). 2001;156(4):481-4.
59. Peth-Nui T, Wattanathorn J, et al. Effects of 12-Week Bacopa monnieri Consumption on Attention, Cognitive Processing, Working Memory, and Functions of Both Cholinergic and Monoaminergic Systems in Healthy Elderly Volunteers. Evid Based Complement Alternat Med. 2012;2012:606424.
60. Dave UP, Dingankar SR, et al. An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention-deficit hyperactivity disorder in children. Adv Mind Body Med. 2014;28(2):10-5.
61. Clayton PT. B6-responsive disorders: a model of vitamin dependency. J Inherit Metab Dis. 2006;29(2-3):317-326.
62. Chandra RK, Sudhakaran L. Regulation of immune responses by vitamin B6. Ann N Y Acad Sci. 1990;585:404-23.
63. Bourre JM. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: micronutrients. J Nutr Health Aging. 2006;10(5):377-85.
64. Douaud G, Refsum H, et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A. 2013;110(23):9523-8.
65. Maggini, S., Wintergerst, E. S., Beveridge, S., and Hornig, D. H. Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. Br J Nutr 2007;98 Suppl 1:S29-S35.
66. Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. Altern Med Rev 2000;5:93-108.
67. O'Leary F, Samman S. Vitamin B12 in health and disease. Nutrients. 2010 Mar;2(3):299-316.
68. Mayer G, Kroger M, Meier-Ewert K. Effects of vitamin B12 on performance and circadian rhythm in normal subjects. Neuropsychopharmacology 1996;15:456-64.
69. Vogel, T., Dali-Youcef, N., Kaltenbach, G., and Andres, E. Homocysteine, vitamin B12, folate and cognitive functions: a systematic and critical review of the literature. Int J Clin Pract 2009;63(7):1061-1067.
70. Syed EU, Wasay M, Awan S. Vitamin B12 supplementation in treating major depressive disorder: a randomized controlled trial. Open Neurol J. 2013;7:44-8.
71. Oh R, Brown DL. Vitamin B12 deficiency. Am Fam Physician. 2003 Mar 1; 67(5):979-86.
72. Banderet LE, Leiberman HR. Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans. Brain Res Bull 1989;22:759-762.
73. Gibson CJ, Wurtman RJ. Physiological control of brain catechol synthesis by brain tyrosine concentration. Biochem Pharmacol 1977;26:11371142.
74. Wurtman RJ, Larin F, Mostafapour S, Fernstrom JD. Brain catechol synthesis: control by brain tyrosine concentration. Science 1974;185:183-184.
75. L-tyrosine. Monograph. Altern Med Rev. 2007;12(4):364-8.
76. Dollins AB, Krock LP, Storm WF, et al. L-tyrosine ameliorates some effects of lower body negative pressure stress. Physiol Behav. 1995;57:223-230.
77. Deijen JB, Orlebeke JF. Effect of tyrosine on cognitive function and blood pressure under stress. Brain Res Bull 1994;33:319-323.
78. Kim DH. Chemical Diversity of Panax ginseng, Panax quinquifolium, and Panax notoginseng. J Ginseng Res. 2012;36(1):1-15
79. Fulder SJ. Ginseng and the hypothalamic-pituitary control of stress. Am J Chin Med. 1981;9(2):112-8.
80. Geng J, Dong J, et al. Ginseng for cognition. Cochrane Database Syst Rev. 2010;(12):CD007769.
81. Lho SK, et al. Effects of lifetime cumulative ginseng intake on cognitive function in late life. Alzheimers Res Ther. 2018;10(1):50.
82. Yakoot M, Salem A, Helmy S. Effect of Memo, a natural formula combination, on Mini-Mental State Examination scores in patients with mild cognitive impairment. Clin Interv Aging 2013;8:975-81.
83. Lee JH, Chung, YS, et al. The effect of Korean traditional alternative medicine products on thyroid function level in post-total thyroidectomy patients: A pilot study. Korean J Clin Oncol 2017; 13(1): 39-42.
84. Smith I, Williamson EM, et al. Effects and mechanisms of ginseng and ginsenosides on cognition. Nutr Rev. 2014;72(5):319-33.
85. Pietta PR. Flavonoids as antioxidants. J Nat Prod. 2000; 63:1035-1042.
86. Grassmann J. Terpenoids as plant antioxidants. Vitam Horm. 2005;72:505-535.
87. Zhang HF, Huang LB, et al. An Overview of Systematic Reviews of Ginkgo biloba Extracts for Mild Cognitive Impairment and Dementia. Front Aging Neurosci. 2016;8:276.
88. Feng L. Ginkgo biloba and cognitive decline. JAMA. 2010 Apr 21;303(15):1477.
89. Wu YZ, Li SQ, et al. Ginkgo biloba extract improves coronary artery circulation in patients with coronary artery disease: contribution of plasma nitric oxide and endothelin-1. Phytother Res. 2008;22(6):734-739.
90. Wu Y, Li S, et al. Ginkgo biloba extract improves coronary blood flow in healthy elderly adults: role of endothelium-dependent vasodilation. Phytomedicine. 2008;15(3):164-169.
91. Nabavi SM, Habtemariam S, et al. Neuroprotective Effects of Ginkgolide B Against Ischemic Stroke: A Review of Current Literature. Curr Top Med Chem. 2015;15(21):2222-2232.
92. Mix JA, Crews WD Jr. A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol. 2002;17(6):267-277.
93. Wesnes KA, Ward T, McGinty A, Petrini, O. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl). 2000;152:353-361.

‍